FR2612398B1 - Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine - Google Patents

Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine

Info

Publication number
FR2612398B1
FR2612398B1 FR8703749A FR8703749A FR2612398B1 FR 2612398 B1 FR2612398 B1 FR 2612398B1 FR 8703749 A FR8703749 A FR 8703749A FR 8703749 A FR8703749 A FR 8703749A FR 2612398 B1 FR2612398 B1 FR 2612398B1
Authority
FR
France
Prior art keywords
decan
chlorophenoxy
aza
oxa
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8703749A
Other languages
English (en)
Other versions
FR2612398A1 (fr
Inventor
Luu Si Nang
Michel Leinot
Aimee Pourrat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Europeen de Recherches Mauvernay CERM
Original Assignee
Centre Europeen de Recherches Mauvernay CERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Europeen de Recherches Mauvernay CERM filed Critical Centre Europeen de Recherches Mauvernay CERM
Priority to FR8703749A priority Critical patent/FR2612398B1/fr
Publication of FR2612398A1 publication Critical patent/FR2612398A1/fr
Application granted granted Critical
Publication of FR2612398B1 publication Critical patent/FR2612398B1/fr
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR8703749A 1987-03-18 1987-03-18 Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine Expired FR2612398B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8703749A FR2612398B1 (fr) 1987-03-18 1987-03-18 Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8703749A FR2612398B1 (fr) 1987-03-18 1987-03-18 Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine

Publications (2)

Publication Number Publication Date
FR2612398A1 FR2612398A1 (fr) 1988-09-23
FR2612398B1 true FR2612398B1 (fr) 1989-07-21

Family

ID=9349153

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8703749A Expired FR2612398B1 (fr) 1987-03-18 1987-03-18 Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine

Country Status (1)

Country Link
FR (1) FR2612398B1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2285873A1 (fr) * 1974-09-27 1976-04-23 Cerm Cent Europ Rech Mauvernay Nouveaux6-aryloxy-2-oxo-1-aza-4-oxa (ou thia)-spiro (4,5) decanes, procede pour leur obtention et application pharmaceutique

Also Published As

Publication number Publication date
FR2612398A1 (fr) 1988-09-23

Similar Documents

Publication Publication Date Title
FR2602974B1 (fr) Composition pharmaceutique contenant de la nicotine ou ses derives
FR2582513B1 (fr) Compositions pharmaceutiques contenant de l'alfuzosine
OA08647A (fr) Dérivés d'imidazole, procédés pour leur préparation et composition pharmaceutique les contenant.
PT87492A (pt) Process for the preparation of benzo ]b" pyrrans and pyranopyridines and pharmaceutical compositions containing them
OA07282A (fr) Composition pharmaceutique lyophilisée contenant de l'interféron procédé pour la préparation et procédé pour sa stabilisation.
EP0315978A3 (en) New use of 11,28-dioxa-4-azatricyclo û22.3.1.0 4,9¨octacos-18-ene derivatives and pharmaceutical compositions containing them
OA07103A (fr) Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant.
FR2626002B1 (fr) Nucleosides dideoxydidehydrocarbocycliques et composition pharmaceutique les contenant
FR2633182B1 (fr) Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
FR2645152B1 (fr) 3h-pteridinones-4, procedes de preparation et medicaments les contenant
MC1915A1 (fr) Procédés pour la préparation de 2',3'-didésoxynucléosides et de formulations pharmaceutiques en contenant
BE887970A (fr) Nouveaux derives d'ocytocine et compositions pharmaceutiques contenant ces derives
OA09190A (fr) "Procédés de préparation de dérivés d'acides benzocycloalcényl dihydroxy alcanoïques et de médicaments les contenant".
PH24326A (en) Substituted 3,4-dihydro-2h-benzopyrans,pharmaceutical compositions containing same and method of use thereof
FR2626175B1 (fr) Composes nouveaux de 1,2-ethylenediamine et composition pharmaceutique les contenant
FR2607502B1 (fr) Derives de l'imidazole, leur preparation et compositions medicamenteuses les contenant
FR2608921B1 (fr) Composition pharmaceutique contenant de la ranitidine
OA08957A (fr) Dérivés d'alcadiènes, leurs préparations, les médicaments les contenant et produits intermédiaires
DE3576505D1 (de) 3,4-dihydrobenzopyranverbindungen und diese enthaltende pharmazeutische zusammenstellungen.
FR2446819B1 (fr) Derives 6-alkyles d'acide 1,2-dihydro-2-oxonicotinique et composition pharmaceutique les contenant
FR2528425B1 (fr) 1,4-dihydropyridines et composition pharmaceutique les contenant
PT84184A (pt) Process for the preparation of 8 alpha-acylaminoergolines and of pharmaceutical compositions containing them
FR2612398B1 (fr) Composition pharmaceutique contenant une association de 6-(3-chlorophenoxy)-2-methyl-1-oxa-4-aza-spiro (4,5) decan-3 one et de b-cyclodextrine
FR2615188B1 (fr) Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant
FR2704857B1 (fr) Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Legal Events

Date Code Title Description
ST Notification of lapse